文献速递妇科

原发性宫颈癌高剂量率组织间插植近距离放疗的前瞻性数据库长期结果

Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma.
PubMed 文献 · Gynecol Oncol · 2016-10-29

本研究基于前瞻性数据库,报告1992至2009年315例不适合单纯腔内近距离放疗的原发性宫颈癌患者接受外照射联合高剂量率组织间插植近距离放疗的长期结局;10年局部控制率87%、总生存率40%,迟发3级泌尿生殖道和胃肠道毒性4.8%、4级5.4%。

要点

  • 315例不适合单纯腔内近距离放疗的宫颈癌患者接受外照射联合高剂量率组织间插植近距离放疗。
  • 10年局部控制率87%、区域控制率84%、总生存率40%。
  • 迟发3级泌尿生殖道和胃肠道毒性4.8%,4级5.4%。

核心结论

  • 模板引导的组织间插植近距离放疗可安全地对局部晚期宫颈癌实施高剂量照射,避免对邻近盆腔重要器官的过量照射和损伤。
  • 在对腔内近距离放疗条件差的患者中,该方案获得了高肿瘤控制率和低并发症率。

研究设计与样本

  • 前瞻性数据库长期结果分析,纳入1992年至2009年接受外照射和高剂量率组织间插植近距离放疗的原发性宫颈癌患者315例,均不适合单纯腔内近距离放疗。
  • 组织学为鳞状细胞癌89%、腺癌8%、腺鳞癌3%;FIGO分期I期14%、II期47%、III期34%、IVA期5%。
  • 中位肿瘤大小6cm;盆腔淋巴结转移26%,腹主动脉旁淋巴结转移9.5%。
  • 治疗计划49%为2D、51%为3D-CT;中位随访50个月,平均随访61个月(范围3-234个月)。

主要发现

  • 10年 actuarial 局部控制率87%,区域控制率84%,局部区域控制率77%。
  • 远处转移无生存率66%,病因特异性生存率56%,无病生存率54%,总生存率40%。
  • 迟发泌尿生殖道和胃肠道毒性3级发生率4.8%,4级发生率5.4%。
  • 中心外照射EQD210平均剂量37.3±4.3Gy(侧壁49.2±3.6Gy),高剂量率近距离放疗EQD210平均剂量42.3±5.3Gy(名义5.4Gy×6次,平均使用24根导管和1根宫腔管)。
  • 总EQD210平均靶区剂量79.5±5.4Gy;标准化计划剂量限值为ICRU点或D0.1cc膀胱为每分次高剂量率剂量的80%、直肠75%、尿道90%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Present long-term outcomes in primary cervical cancer treated with external beam and high dose rate interstitial brachytherapy. METHODS: High dose rate (HDR) interstitial (IS) brachytherapy (BT) and external beam (EBRT) were administered from 1992 to 2009 to 315 patients who were unsuitable for intracavitary (IC) BT alone. Histology was 89% squamous cell, 8% adenocarcinoma, and 3% adenosquamous. FIGO stage was I-14%, II-47%, III-34%, and IVA-5%. Median tumor size was 6cm. Lymph node metastases were 26% pelvic and 9.5% para-aortic. Treatment planning was 49% 2D and 51% 3D-CT. The mean doses were central EBRT EQD210 37.3±4.3Gy (sidewall 49.2±3.6Gy) and HDR EQD210 42.3±5.3Gy (nominal 5.4Gy×6 fractions using a mean of 24 catheters and 1 tandem). Total EQD210 mean target dose was 79.5±5.4Gy. Standardized planned dose constraints were ICRU points or D0.1cc bladder 80%, rectum 75% and urethra 90% of the HDR dose per fraction. Morbidity assessment was CTCAEv3. Median and mean follow-up were 50 and 61months (3-234). RESULTS: The 10-year actuarial local control was 87%, regional control 84%, and loco-regional control 77%. Distant metastasis free survival was 66%, cause specific survival 56%, disease free survival 54%, and overall survival 40%. The rates of late grade GU and GI toxicities were 4.8% G3 and 5.4% G4. CONCLUSIONS: Template-guided interstitial can be safely performed to successfully deliver high radiation dose to locally advanced cervix cancer and avoid excessive dose and injury to adjacent vital pelvic organs. We achieved high tumor control with low morbidity in patients who were poor candidates for intracavitary brachytherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fallon J, Park SJ, Yang L, et al. Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma. Gynecol Oncol. 2016. PMID: 28029448. doi:10.1016/j.ygyno.2016.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。